Future Cardia offering is now closed and is no longer accepting investments.

INVEST IN FUTURE CARDIA TODAY!

Voice of the Heart

We are Future Cardia (Oracle Health, Inc.) - Bringing you a tiny insertable cardiac monitor for a long-term heart failure monitoring solution to disrupt the $5B market and to set the stage for Connected Implants. Our approach is a simple 2-minute office procedure that brings simplicity, accuracy, high compliance for long-term monitoring, and existing insurance coverage.

This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Future Cardia

$3,045,157 Raised

Offering Circular Supplement  Risks Related to this Offering |  SEC EDGAR Filings

Reasons to Invest



  • World-renowned cardiologists, engineers and scientists: with over 180 years of combined expertise in cardiology and medical devices development with multiple exits and one IPO. 
  • Raised $4M ($3.3m on Republic and $700K from Super Angels) in 2021 to disrupt the $5B Heart Failure monitoring market. 
  • Stanford StartX: is the premier accelerator program in the world with one of the highest success rates along with 10 startups achieving unicorn status in the past 12 years. StartX companies have a combined valuation of over $30B and 92% survival rate. Over 300 Silicon Valley mentors participate in the program.
  • Johnson and Johnson's JLABS: is a global network of open innovation ecosystems, enabling and empowering innovators to accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS companies have a combined valuation of $9.4B. Five IPOs, Eight acquisitions.



OVERVIEW


Cardiologist and Patients Deserve a Better Option

Cardiologists today lack good options for monitoring their heart failure patients at home. Future Cardia is developing an implanted remote cardiac monitor to address this problem. Designed to provide comprehensive data and analysis to doctors, Future Cardia also aims to build the largest collection of long-term cardiac data to improve the lives of patients. 

  • Detects early signs of Heart Failure problems before symptoms
  • Pre-clinical testing with 26 heart failure patients
  • Preparing for lab testing and then human implant in 2022 using Electrocardiogram (ECG) and heart sounds with remote monitoring technology to monitor heart
  • Provides actionable and quantifiable data analytics for the cardiologists

THE PROBLEM


Heart Failure Emergencies are a $21 Billion a Year Problem


A lack of remote Heart Failure monitoring solutions makes it difficult for heart failure patients and healthcare providers to address emergencies. As a chronic disease, our patients and physicians are stuck between real emergencies and false alarms, resulting in referral to the Emergency Department and subsequent admission to the hospital, even if it is a false alarm.   



Heart failure is a cardiac condition that often results in breathing problems and frequent hospitalizations. Heart Failure patients have weakened heart muscles. As the heart begins to fail, fluid slowly accumulates in the lungs, which can lead to sudden and severe breathing problems.


In the US alone, six million patients suffer from Heart Failure. Canada and Europe are facing the same problem. Because of the lack of a remote monitoring solution for Heart Failure, patients are referred to the ER and subsequently hospitalized, even if it is a false alarm.


Invasive heart procedure devices such as CardioMems by Abbott (acquired for $455 million) are the current standard. This device requires a sensor implant inside the heart or around the heart (Pulmonary Artery) in a cath lab procedure. Accurate, however, they are expensive, complex and are not the ideal solution for all patients.


Wearable monitors are ideal for short-term solutions, however, they suffer from low accuracy, patient non-compliance, and limited data. Therefore, they have a limited use when it comes to long-term Heart Failure monitoring.


THE market



$5 Billion Total Addressable Market Opportunity

Initially, Future Cardia will focus on the one million patients suffering from heart failure, who are in immediate need of remote monitoring solutions. Eventually we hope to reach all six million Americans who suffer from heart failure.

THE solution


A Cardiac Monitor Using Remote Monitoring Technology and AI


Future Cardia is developing a tiny, insertable cardiac device to monitor Heart Failure and reduce unnecessary hospitalizations. The device utilizes multi-sensors, remote monitoring technology and cloud based Artificial Intelligence for long-term comprehensive cardiac monitoring. 


This is a simple 2-minute office procedure that does not require a follow up, saving time for both patients and cardiologists. The device is inserted under the skin for improved accuracy, and does not require invasive surgery that other implanted devices do.    





By tracking trends in ECG and Heart Sounds readings, physicians can detect heart failure decompensation before the onset of symptoms. This gives them actionable data to steer the patient away from further complications.  


Billions of data points for a comprehensive long term cardiac monitoring solution


Future Cardia is developing a compact cardiac device that is inserted subcutaneously (under the skin) in a two-minute office procedure. Once administered, each device yields billions of data points, allowing healthcare providers to compare trending changes over 2-3 years for continuous cardiac monitoring. As Future Cardia collects more data, the analysis will improve through the use of machine learning and AI using ECG and Heart Sounds as biomarker for Cardiology.


Our product relies on three main features: an acoustic sensor, an ECG, and a 3-Axis Accelerometer. The acoustic sensor listens to heart and lung sounds, while the Electrocardiogram (ECG) records heart rhythms and 3-Axis Accelerometer records activity, posture and body orientation.


Our device has high patient compliance over the long-term, because patients do not need to follow a complex process to monitor their cardiac health.


Recorded cardiac data is securely transmitted to a smartphone, then to a cloud-based Artificial Intelligence algorithm for analysis, which the cardiologist can then review and take action.


By analyzing electrical and physiological trends, Future Cardia detects early signs of cardiac decline even before symptoms appear. This allows clinicians to prioritize at-risk patients, implement therapeutic interventions, and prevent hospitalizations. 



why invest


Short Regulatory Path with Existing Insurance Coverage of $7,400 / Device for Commercialization 






Future Cardia has a simple go-to-market plan. First, we will focus on two highest volume regions, Texas and Florida. We expect Texas and Florida to generate $5.5 million within two years of launch. Each unit will retail for $5,300/unit with an established reimbursement of $7,400 (insurance coverage). With this business model, we project that our first 5K implants will generate $26M in revenue within 4 years. 


Second, we will obtain the most comprehensive, long-term cardiac data to date as biomarkers for cardiology. This will allow Future Cardia to venture into predictions for cardiac events, and human longevity study.  


AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.

THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE [https://www.sec.gov/Archives/edgar/data/1777274/000121390021002171/ea133381-253g1_oraclehealth.htm].

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.


Future Cardia 17b Disclosure

Insert Image
Drop image
(or click)

Loading image

ABOUT

HEADQUARTERS
2450 Holcombe Blvd suit J
Houston, TX 77021

We are Future Cardia (Oracle Health, Inc.) - Bringing you a tiny insertable cardiac monitor for a long-term heart failure monitoring solution to disrupt the $5B market and to set the stage for Connected Implants. Our approach is a simple 2-minute office procedure that brings simplicity, accuracy, high compliance for long-term monitoring, and existing insurance coverage.

TEAM

Jaeson Bang
Jaeson Bang
Founder & CEO

-Heart Failure Clinical, Technology and Business operations for the past 18 years with Medtronic and Silicon Valley Startups.

-Extensive background in sales and product development in implantable devices operations.

-Kellogg MBA

Dimitrios Georgakopoulos, PhD

Dimitrios Georgakopoulos, PhD

Director of Science

- Heart Failure and Cardiac Hemodynamics scientist at Startups and a NASDAQ company.

- Held Chief Science Officer position at a NASDAQ company.

- PhD from Johns Hopkins

Dr. Dan Burkhoff, MD PhD

Dr. Dan Burkhoff, MD PhD

Medical Advisor

- World-renowned Physician Scientist with med tech startup and Heart Failure expertise.

- Multiple exits. 

- Served at a VP at Heartware, which was acquired by Medtronic for $1.2B.

Dr. Kevin Heist, MD PhD

Dr. Kevin Heist, MD PhD

Medical Advisor

- Stanford MD PhD, currently at Harvard.

- Cardiologist with his specialty in the field of Electrophysiology to treat Cardiac Arrhythmias. 

- Currently practicing at Mass General Hospital in Boston.

Anatoly Yakovlev, PhD

Anatoly Yakovlev, PhD

Data Scientist

- Stanford PhD with expertise in neuromodulations and AI.

- Electrical Engineering and PhD from Stanford University. 

- Currently working on AI at a top software company in Silicon Valley.

Professor Frits Prinzen, PhD

Professor Frits Prinzen, PhD

Scientist

- World's foremost expert in Cardiac Mechanics and Hemodynamics scientist.

- Architect of commonly used cardiac models and publisher of landmark research.

Dr. Toshi Okabe, MD

Dr. Toshi Okabe, MD

Medical Advisor

- Electrophysiology Cardiologist from Ohio State University.

- Expertise in managing cardiac arrhythmia and cardiac ablations.

Dr. David Kraus, MD

Dr. David Kraus, MD

Medical Advisor

- Heart Failure and Cardiac Transplant Physician.

- Top clinical trialist in the US.

TERMS

Future Cardia
Overview
PRICE PER SHARE
$2
DEADLINE
Jun 21, 2022
VALUATION
$20M
AMOUNT RAISED
$3,045,157
Breakdown
MIN INVESTMENT
$250
MAX INVESTMENT
$100,000
MIN NUMBER OF SHARES OFFERED
0
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
2,355,221

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Oracle Health, Inc.

Corporate Address

:

2450 Holcombe Blvd suit J, Houston, TX 77021

Offering Minimum

:

$0.00

Offering Maximum

:

$8,000,000.00

Minimum Investment Amount

(per investor)

:

$250.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

0

Maximum Number of Shares Offered

:

4,000,000

Price per Share

:

$2.00

Pre-Money Valuation

:

$20,000,000.00











No perks

PRESS

Article Image
Tech Nori

Oracle Health's tiny, non-invasive heart monitor is one-of-a-kind | Technori Pitch

Article Image
Florida Venture Forum

2021 Early Stage Capital Conference

Article Image
Space Florida

Space Florida, Florida Venture Forum Announce Award Winners from 2021 Florida Early Stage Capital Conference and Statewide Collegiate Startup Competition

Article Image
Tampa Bay Wave

Congratulations to Jaeson Bang of Oracle Health for being awarded $20K at the 2021 Florida Early Stage Capital Conference, held by Space Florida and the Florida Venture Forum!

Article Image
St. Pete Catalyst

Medical device startup raises nearly $1M via crowdfunding campaign

ALL UPDATES

06.20.22

Less than 24 Hours Left


Hello StartEngine Investor Community. 

We are getting close to finalizing our offer. 

And huge thanks to our investors, we have raised over $2.9M on StartEngine. 

If our investors add an additional $250, then we can reach well over $3M. 

Your investment is allowing us to be scrappy and fast! Will stay vigilant for our patients, physicians and you the investor! 

Please help us finish this offering strong!! 

Thank you. 


Jae B 

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

06.19.22

Final Hours to Invest


Hello StartEngine Investor Community. 

We are getting close to finalizing our offer. 

And huge thanks to our investors, we have raised over $2.8M on StartEngine. 

If our investors add an additional $250, then we can reach well over $3M. 

Your investment is allowing us to be scrappy and fast! Will stay vigilant for our patients, physicians and you the investor! 

Please help us finish this offering strong!! 

Thank you. 


Jae B 

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

06.18.22

48 Hours Remaining - Let's finish strong




Hello StartEngine Investor Community. 

We are getting close to finalizing our offer. 

And huge thanks to our investors, we have raised over $2.8M on StartEngine. 

If our investors add an additional $250, then we can reach well over $3M. 

Your investment is allowing us to be scrappy and fast! Will stay vigilant for our patients, physicians and you the investor! 

Please help us finish this offering strong!! 

Thank you. 


Jae B 

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

06.17.22

Final 3 Days Remaining


Hello StartEngine Investor Community. 

We are getting close to finalizing our offer to our investors. 

And huge thanks to so many of our investors that have invested again. We have raised over $2.7M from investors like you. 

If our investors add an additional $250, then we can reach well over $3M. 

Please help us finish this offering strong!! 

Thank you. 


Jae B

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

06.16.22

US Patent Office and Future Cardia


Dear Investors, 

We are making solid progress on our Patent Process. 

We are pleased to report that we have now received a Notification from the United States Patent and Trademark Office (USPTO), indicating that our Petition to Convert Application to a Provisional Application has been Granted. 

Thank you so much for your support!! 


Jae B

06.15.22

Implant Update - Future Cardia



Dear StartEngine Investor Community, 

As we reach the final days of offering, I would like to update you on our implant status. 

Our engineering team gathered in to build a beautiful device that will be implanted this week. 

Our algorithm is working very nicely, as we will test for automatic sensing and detection software. 

It will continuously look at the normal rhythm and start to record when it becomes irregular. 

Hugely complex and delicate operation, but we are confident we will achieve it this week. 

All our activities are possible because of you the investor!!

Thank you. 


Jae B

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.  In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

06.14.22

$2.5M in Investment


Dear StartEngine Investors, 

Thank you so much for your support! 

We have surpassed $2.5 Million in investments from StartEngine investor community. 

-NDA signed with a top medical device company 

-Lab Implant #2 

- Sensing and Detection 

-Human implant on schedule 

-hired regulatory team in US and EU


Thank you and more to follow!! 

Jae B 

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.  In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

06.11.22

Artificial Intelligence and Future Cardia

Dear StartEngine Investors, 

We have analyzed the cardiac data from our lab testing. 

We can see the electrical and mechanical aspects of the heart that is represented by ECG and Heart Sounds. 

And then applied Artificial Intelligence to those data

They are short, but it is a huge step for us to human implant and subsequent data analytics. 

Thank you. 

Jae B 

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

06.08.22

NDA Signed with a Top Medical Device Company

Dear StartEngine Investor Community, 

Today at Heart Rhythm Society, we have signed a Nondisclosure Agreement (NDA) with one of the biggest med tech companies in the world.

This will allow us to discuss and potentially collaborate that will heighten our presence in Cardiac Devices stage. 

More to follow. 

Thank you. 


Jae B 

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

06.06.22

2 Weeks Remaining

Dear StartEngine Investor Community. 

Thank you for your investment in us. 

We would not be here without your support. We have reached the final 14 days before we close the offering. 

Your funding is allowing us to challenge the old guards at our term. 

This allows us to be scrappy, aggressive, and agile.

We believe the current corporations have been sitting on a multi-billion dollar industry with little innovation. 

We hope to change that and bring value to patients, physicians and you the investors.

Thank you. 


Jae B 

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

PREVIOUSLY CROWDFUNDED
$3,289,558
RAISED
$3,045,157
INVESTORS
2,274
MIN INVEST
$250
VALUATION
$20M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.